Conformis, Inc. v. DePuy Synthes, Inc.

CourtDistrict Court, D. Delaware
DecidedAugust 9, 2023
Docket1:21-cv-00640
StatusUnknown

This text of Conformis, Inc. v. DePuy Synthes, Inc. (Conformis, Inc. v. DePuy Synthes, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Conformis, Inc. v. DePuy Synthes, Inc., (D. Del. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

CONFORMIS, INC., Plaintiff, V. Civil Action No. 21-640-RGA DEPUY SYNTHES, INC., DEPUY SYNTHES PRODUCTS, INC., and DEPUY SYNTHES SALES, INC., Defendants.

MEMORANDUM ORDER This Memorandum Order addresses the issue of claim construction of multiple terms in U.S. Patent No. 8,623,026 (the “’026 Patent’), U.S. Patent No. 8,377,129 (the “’129 Patent”), U.S. Patent No. 9,186,161 (the “’161 Patent”), U.S. Patent No. 8,460,304 (the “’304 Patent”), and U.S. Patent No. 9,295,482 (the “’482 Patent”), and U.S. Patent No. 9,326,780 (the “’780 Patent”) (the “Asserted Patents”). The parties submitted a Joint Claim Construction Brief addressing seven disputed terms. (D.I. 102 (terms A through G)). I heard oral argument on April 18, 2023. (D.I. 124). Before the Markman hearing, I proposed tentative constructions for the disputed terms. (D.I. 116). In response to my tentative constructions, the parties agreed that “no oral argument is necessary” for three of the seven terms. (D.I. 119 (terms A, C, and D)). After the hearing, the parties agreed to defer consideration of two terms to a later stage of the case. (D.I. 121 (term E), D.I. 147 (term F)). The parties filed supplemental briefing on the two remaining terms. (D.I. 125, 128, 132 (term G, “mold”); D.I. 126, 127, 133 (term B, “includes/including”)). I turn to those two terms now.

I. BACKGROUND The Asserted Patents relate to patient-specific surgical tools and systems for use in joint- replacement surgery or joint arthroplasty. (D.I. 102 at 4). The Asserted Patents are part of the same family and claim dependency from common patent applications. The ’780 Patent is a continuation from the ’026 Patent application (U.S. Patent Application No. 13/207,396). (Ud. at 4-5). The 7129 and °304 Patents are continuations of Application No. 10/724,010 and have substantively identical specifications. (/d. at 4). Similarly, the ?161 and ’482 Patents are continuations of Application No. 12/048,764 (which became the ’745 Patent) and have substantively identical specifications. (/d.). Il. LEGAL STANDARD “It is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc) (internal quotation marks omitted). “‘[T]here is no magic formula or catechism for conducting claim construction.’ Instead, the court is free to attach the appropriate weight to appropriate sources ‘in light of the statutes and policies that inform patent law.’” SoftView LLC v. Apple Inc., 2013 WL 4758195, at *1 (D. Del. Sept. 4, 2013) (alteration in original) (quoting Phillips, 415 F.3d at 1324). When construing patent claims, a court considers the literal language of the claim, the patent specification, and the prosecution history. Markman v. Westview Instruments, Inc., 52 F.3d 967, 977-80 (Fed. Cir. 1995) (en banc), aff'd, 517 U.S. 370 (1996). Of these sources, “the specification is always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term.” Phillips, 415 F.3d at 1315 (internal quotation marks omitted). “[T]he words of a claim are generally given their ordinary and customary meaning...., [which is] the meaning that the term would have to a person of ordinary skill in the art in question at the

time of the invention, i.e., as of the effective filing date of the patent application.” Jd. at 1312-13 (citations and internal quotation marks omitted). “[T]he ordinary meaning of a claim term is its meaning to [an] ordinary artisan after reading the entire patent.” Jd. at 1321 (internal quotation marks omitted). “In some cases, the ordinary meaning of claim language as understood by a person of skill in the art may be readily apparent even to lay judges, and claim construction in such cases involves little more than the application of the widely accepted meaning of commonly understood words.” /d. at 1314. When a court relies solely upon the intrinsic evidence—the patent claims, the specification, and the prosecution history—the court’s construction is a determination of law. See Teva Pharms. USA, Inc. v. Sandoz, Inc., 574 U.S. 318, 331 (2015). The court may also make factual findings based upon consideration of extrinsic evidence, which “consists of all evidence external to the patent and prosecution history, including expert and inventor testimony, dictionaries, and learned treatises.” Phillips, 415 F.3d at 1317-19 (quoting Markman, 52 F.3d at 980). Extrinsic evidence may assist the court in understanding the underlying technology, the meaning of terms to one skilled in the art, and how the invention works. /d. Extrinsic evidence, however, is less reliable and less useful in claim construction than the patent and its prosecution history. Jd. “[A] patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention.” Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898, 901 (2014). Inferring indefiniteness because a claim’s scope is broad, however, is “legally incorrect: ‘breadth is not indefiniteness.’” BASF Corp. v. Johnson Matthey Inc., 875 F.3d 1360, 1367 (Fed. Cir. 2017) (quoting SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331,

1341 (Fed. Cir. 2005)). The party raising indefiniteness bears the burden of proving it by clear and convincing evidence. See BASF, 875 F.3d at 1365 (Fed. Cir. 2017). Ili. PATENTS AT ISSUE The parties agree that, for claim construction purposes, the following claims are representative. (D.I. 102 at 7-9; D.I. 125 at 1-2; D.I. 127 at 1-3). A. °161 Patent 1. A surgical system including an articular repair system and a surgical instrument for use in surgically repairing a joint of a patient, the surgical instrument comprising: a mold having an internal surface that includes joint information derived from image data of the joint of the patient; and two or more guide holes, each configured to guide a surgical pin, wherein at least one of the two or more guide holes has a position and/or orientation based on anatomical information of the joint of the patient to facilitate the placement of the articular repair system when the internal surface of the mold is aligned with the joint of the patient, wherein the articular repair system has a predetermined rotation angle and wherein the position and/or orientation is based on the predetermined rotation angle. Patent, Claim 1) (disputed terms bolded). B. °304 Patent 1.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Conformis, Inc. v. DePuy Synthes, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/conformis-inc-v-depuy-synthes-inc-ded-2023.